AstraZeneca reports bumper revenue in Q1 2024 on strong drug demand
Pharmaceutical giant AstraZeneca reported its first quarter 2024 earnings on Thursday, seeing extremely robust earnings per share (EPS) and revenue growth. This was mainly due to continuously growing partner drug sales, as well as increasing demand for the company’s best-selling medicines. Total revenue soared 19% to $12,679 million (€11,818.1 million) year-on-year, primarily boosted by an 18% growth in product sales. Total revenue for oncology jumped 26%, with respiratory and immunology revenue rising 17% and cardiovascular, renal and metabolism revenue inching up 23%. Rare disease revenue ad...